Microneedles as an alternative technology for transdermal drug delivery systems: a patent review [0.03%]
微针作为经皮给药系统的技术替代品：专利综述
Monna Lisa Barreto Queiroz,Saravanan Shanmugam,Lana Naiadhy Silva Santos et al.
Monna Lisa Barreto Queiroz et al.
Introduction: The most conventional drug delivery systems exist with limitations such as drug degradation, toxicity and low bioavailability. Also, hypodermic injections can cause pain, compromising patient compliance. Due to this, transderm...
Challenges in the development of next-generation antibiotics: opportunities of small molecules mimicking mode of action of host-defense peptides [0.03%]
下一代抗生素开发中的挑战：小分子模拟宿主防御肽作用机制的机遇
Minghui Wang,Timothy Odom,Jianfeng Cai
Minghui Wang
A patent review of anticancer glucocorticoid receptor modulators (2014-present) [0.03%]
2014年至今抗肿瘤糖皮质激素受体调节剂专利回顾
Marianna Lucafò,Martina Franzin,Giuliana Decorti et al.
Marianna Lucafò et al.
Introduction: Natural and synthetic glucocorticoids are widely employed in different diseases, among which are hematological and solid tumors. Their use is however associated with a number of serious side effects and by the occurrence of re...
Tropomyosin receptor kinase inhibitors: an updated patent review for 2016-2019 [0.03%]
tropomyosin受体激酶抑制剂：2016-2019年专利回顾更新
Justin J Bailey,Carolin Jaworski,Donovan Tung et al.
Justin J Bailey et al.
Introduction: Tropomyosin receptor kinases (Trks) control processes in the fields of growth, survival, and differentiation of neuronal processes. They also play a crucial role in neurodegenerative diseases as well as different types of canc...
Anaplastic lymphoma kinase inhibitors: an updated patent review (2014-2018) [0.03%]
间变性淋巴瘤激酶抑制剂的专利回顾（2014-2018）
Yi-Min Liu,Chun-Nan Kuo,Jing-Ping Liou
Yi-Min Liu
Introduction: Anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase, has been discovered in several cancers, including anaplastic large-cell lymphoma, non-small cell lung cancer, and inflammatory myofibroblastic tumors. The deregulat...
Colon carcinoma treatment using bispecific anti-GITR/CTLA-4 antibodies: a patent evaluation of WO2018091739 [0.03%]
一种用于结肠癌治疗的双特异性的抗GITR/CTLA-4抗体：评估WO2018091739专利申请
Lourdes Millán-Pérez Peña,Perez-Santos Martin,Irma Herrera-Camacho et al.
Lourdes Millán-Pérez Peña et al.
Introduction: GITR is a receptor that increases the activation of T lymphocytes against tumor cells. There is a great need to discover and develop new therapies focused on activating GITR to increase the immune response in various types of ...
A patent review of discoidin domain receptor 1 (DDR1) modulators (2014-present) [0.03%]
2014年至今盘状胶原受体1(DDr1)调节剂的专利分析
Jing Guo,Zhen Zhang,Ke Ding
Jing Guo
Introduction: Discoidin domain receptor 1 (DDR1) is a collagen-activated receptor tyrosine kinase. Upon collagen binding, DDR1 undergoes tyrosine autophosphorylation, which consequently triggers downstream genetic and cellular pathways and ...
Hedgehog signaling pathway inhibitors: an updated patent review (2015-present) [0.03%]
刺猬信号通路抑制剂专利回顾(2015-至今)
Deborah Quaglio,Paola Infante,Lucia Di Marcotullio et al.
Deborah Quaglio et al.
Introduction: Hedgehog (Hh) signaling plays a pivotal role in tissue development and stemness, and its deregulation is found in many different tumors. Several efforts have been devoted to discovery of Hh inhibitors, including three drugs ap...
A patent review of apelin receptor (APJR) modulators (2014-2019) [0.03%]
2014-2019年APELIN受体(APJR)调节剂专利综述
Conrad Fischer
Conrad Fischer
Introduction: The apelinergic system is regarded as a novel therapeutic target for cardiovascular health, fluid homeostasis, the hypothalamic-pituitary-adrenal (HPA) axis as well as carbohydrate and fat metabolism. Two endogenous peptide li...
Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-present) [0.03%]
LRKK2抑制剂专利回顾（2014-今）
Xiao Ding,Feng Ren
Xiao Ding
Introduction: Disease-modifying treatment for Parkinson's disease (PD) to halt or revert the disease progression remains an unmet medical need. LRRK2 kinase activity is abnormally elevated in PD patients carrying LRRK2 mutations, with G2019...